mao-b

MAO-B-IN-30 is a selective and potent MAO-B inhibitor that crosses the blood-brain barrier with antiproliferative activity and inhibits both MAO-A and MAO-B.MAO-B-IN-30 reduces the levels of TNF-alpha, IL-6, and NF-kB in organisms, and can be used to study Parkinson's-type neurological disorders.

C5 is a highly efficient and selective MAO-B inhibitor.

MAO-B inhibitor 58 is an effective, selective, and reversible inhibitor of monoamine oxidase B.

MAO-B-IN-17 is a selective and potent monoamine oxidase B (MAO-B) inhibitor (IC50: 5.08 μM) used in the study of central nervous system disorders, including Parkinson's.

5-HT6R/MAO-B modulator 1 is an antagonist of 5-HT6R (at Gs signaling) and an irreversible inhibitor of MAO-B that exhibits glial protective activity and induces scopolamine-induced memory deficits.

MAO-B ligand-1 is a selective MAO-B inhibitor.

hMAO-B-IN-32 is a potent hMAO-B selective inhibitor with an IC50 of 45.52 μM.

AChE/BChE/MAO-B-IN-1 is a reversible, non-time-dependent inhibitor of AChE, BChE, and MAO-B that crosses the blood-brain barrier, exhibiting inhibitory effects on hAChE, hBChE, and hMAO-B with IC50s of 7.31, 0.56, and 26.1 μM, respectively. [AChE/BChE/MAO-B-IN-1] had a neuroprotective effect and was not significantly cytotoxic.

MAO-B-IN-1 is a monoamine oxidase B inhibitor and can be used for the research of neurological diseases.

MAO-B-IN-5 is a potent, selective, and orally active MAO-B inhibitor with an IC50 of 0.204 μM, showing potential for research in Parkinson's disease (PD) [1].

MAO-B-IN-8 is a highly potent and reversible inhibitor of monoamine oxidase-B (MAO-B), also inhibiting microglial production of neuroinflammatory mediators. This compound is specifically designed for research on neurodegenerative diseases [1].

hMAO-B-IN-4 is a selective, reversible and blood–brain barrier (BBB) penetrable inhibitor of human monoamine oxidase-B (hMAO-B, IC50=0.067 μM, Ki= 0.03 μM, hMAO-A, IC50= 33.82 μM).

MAO-B-IN-2 is a selective and competitive inhibitor of MAO-B and BChE with IC50 values of 0.51 μM and 7.00 μM, respectively. It attenuates H2O2-induced cellular damage due to its strong ROS scavenging properties.

MAO-B-IN-36 (Compound A6) is an effective MAO-B inhibitor with an IC50 of 13 nM.

hMAO-B-IN-10 (compound 7) is an inhibitor of MAO-A/B with IC50 values of 424.1 nM and 177.9 nM, respectively. It has demonstrated neuroprotective effects in the MPTP-induced mouse model of Parkinson's Disease (PD).

MAO-B-IN-37 (Compound 37) is a derivative of TT01001 and acts as a selective inhibitor of monoamine oxidase B (MAO-B), with an IC50 of 270 nM. It exhibits good metabolic stability in mouse microsomes and shows strong affinity for human serum albumin.

MAO-B-IN-38 (Compound 6b) is a reversible, competitive inhibitor of MAO-B, exhibiting IC50 values of 0.03 µM for MAO-B and 21.46 µM for MAO-A. This compound is applicable in research on neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

AChE/MAO-B-IN-7 (VAV-8) is a compound that acts as a dual inhibitor of acetylcholinesterase (AChE) and MAO-B, with the ability to cross the blood-brain barrier. It also inhibits the aggregation of Aβ42, making it a valuable compound for Alzheimer's disease (AD) research.

MAO-B-IN-39 (compound11) is a potent inhibitor of monoamine oxidase B (MAO-B), with an IC50 of 3.61 μM. It demonstrates strong NRF2 induction capabilities and exhibits significant anti-inflammatory and neuroprotective effects in oxidative stress-related in vitro models. Additionally, MAO-B-IN-39 shows high liver microsomal stability and favorable pharmacokinetic properties in mice, making it a valuable compound for Parkinson's disease research.

MAO-B-IN-40 (3a) is an inhibitor of MAOB, exhibiting an IC50 value of 0.493 μM against hMAOB, and demonstrates significant neuroprotective and antioxidant effects. MAO-B-IN-40 (3a) is applicable in Parkinson's disease research.

AChE/BChE/MAO-B-IN-5 is a multi-target inhibitor capable of crossing the blood-brain barrier, targeting cholinesterases (AChE and BChE) and monoamine oxidase MAO-B. It exhibits IC50 values of 0.24 µM for AChE, 6.29 µM for BChE, and 0.11 µM for MAO-B. AChE/BChE/MAO-B-IN-5 holds potential for research in neurodegenerative diseases such as Alzheimer's disease.

hMAO-B-IN-11 (Compound 12) is a selective and reversible inhibitor of human monoamine oxidase B (hMAO-B) with an IC50 value of 0.11 µM. It operates by competitively binding to the active site of hMAO-B, thereby preventing the oxidative deamination of monoamines and reducing hydrogen peroxide production. Additionally, hMAO-B-IN-11 inhibits pro-inflammatory mediators (NO, TNF-α, IL-1β) in activated microglia. This compound holds potential for research in neurodegenerative diseases such as Parkinson's and Alzheimer's.

MAO-B-IN-42 (Compound 4f) is a selective and reversible monoamine oxidase-B (MAO-B) inhibitor, with an IC50 value of 0.184 μM. By blocking the oxidative deamination of monoamines catalyzed by MAO-B, it helps maintain neurotransmitter levels. MAO-B-IN-42 shows potential for research into Parkinson's disease.

MAO-B-IN-43 (4) is a potent inhibitor of hMAO-B and a mild inhibitor of GSK3β kinase, with Ki values for hMAO-A and hMAO-B of 0.044 μM and 0.004 μM, respectively. This compound is applicable in the study of neurodegenerative diseases.